August 08, 2008
Faegre & Benson Represents Affinity BioReagents in Acquisition by Thermo Fisher Scientific
Press Release
Faegre & Benson LLP recently represented Affinity BioReagents, Inc., a Golden, Colorado-based company, in its acquisition by Thermo Fisher Scientific Inc.
With an offering of more than 35,000 reagents, Affinity BioReagents is a leading provider of antibodies, peptides and proteins for life science research. Thermo Fisher Scientific (NYSE: TMO) is a leader in the international health and science community, with over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies.
John R. Marcil, a corporate partner in the firm's Boulder office, served as lead attorney on the deal with support from Matt Stamski.
Related Professionals
